Funding Round attributes
Nuclera, a biotech firm based in Cambridge, has successfully raised $75 million in a Series C funding round led by Elevage Medical Technologies, Patient Square Capital, and joined by British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D. McCreary, Uni Power Group, and Verve Ventures. The investment will be used to advance the commercial development of Nuclera's eProtein Discovery system, a benchtop platform designed to expedite protein expression and purification. This system allows scientists to access high-quality proteins in under 48 hours, significantly speeding up drug discovery and other research processes. The funding will also fuel the company’s expansion in the U.S. and Europe, with existing investors like British Patient Capital and Cambridge Innovation Capital continuing their support.
The eProtein Discovery system automates the protein production process, which is traditionally labor-intensive and time-consuming. By streamlining these tasks, Nuclera aims to revolutionize the fields of biotechnology and pharmaceutical development. The company’s CEO highlighted that this funding would enable further product development and allow the firm to meet the increasing global demand for faster and more efficient protein discovery methods. The participation of new and existing investors underscores strong confidence in the company’s ability to deliver a transformative solution for researchers and drug developers worldwide.
Elevage Medical Technologies, the lead investor, expressed optimism about the potential impact of Nuclera's technology, emphasizing the importance of reducing bottlenecks in protein research and development. The $75 million raised in this round will also support Nuclera’s efforts to scale its operations, enhance its product offerings, and continue to provide innovative solutions that address critical challenges in biotechnology.
With this funding, Nuclera is poised to make significant strides in bringing its eProtein Discovery system to a wider audience, positioning itself as a key player in the global biotechnology landscape.
